Myovant Sciences Ltd. (MYOV) Income Statement Analysis

See more : Osiris Corporation (OSRS) Income Statement Analysis – Financial Results

Complete financial analysis of Myovant Sciences Ltd. (MYOV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Myovant Sciences Ltd., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Rupert Resources Ltd. (RUP.TO) Income Statement Analysis – Financial Results
Balmer Lawrie & Co. Ltd. (BALMLAWRIE.BO) Income Statement Analysis – Financial Results
Heritage Distilling Holding Company, Inc. Common Stock (CASK) Income Statement Analysis – Financial Results
Pacific Edge Limited (PEB.AX) Income Statement Analysis – Financial Results
IAA, Inc. (IAA) Income Statement Analysis – Financial Results

Myovant Sciences Ltd. (MYOV)

Industry: Biotechnology

Sector: Healthcare

Website: https://myovant.com

About Myovant Sciences Ltd.

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

Metric	2022	2021	2020	2019	2018	2017
Revenue	230.97M	59.32M	0.00	0.00	0.00	0.00
Cost of Revenue	51.55M	1.97M	0.00	0.00	0.00	0.00
Gross Profit	179.42M	57.35M	0.00	0.00	0.00	0.00
Gross Profit Ratio	77.68%	96.69%	0.00%	0.00%	0.00%	0.00%
Research & Development	107.40M	136.71M	192.56M	222.61M	116.83M	43.50M
General & Administrative	0.00	0.00	82.33M	42.22M	24.23M	12.36M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	259.36M	181.42M	82.33M	42.22M	24.23M	12.36M
Other Expenses	40.04M	1.66M	1.62M	-309.00K	67.00K	-139.00K
Operating Expenses	366.77M	318.14M	274.89M	264.83M	141.06M	55.86M
Cost & Expenses	418.32M	320.10M	274.89M	264.83M	141.06M	55.86M
Interest Income	384.00K	211.00K	2.55M	881.00K	0.00	0.00
Interest Expense	13.97M	10.40M	12.66M	8.82M	2.05M	0.00
Depreciation & Amortization	3.46M	2.69M	1.77M	438.00K	243.00K	61.00K
EBITDA	-183.89M	-258.09M	-273.80M	-255.88M	-140.75M	0.00
EBITDA Ratio	-79.62%	-435.11%	0.00%	0.00%	0.00%	0.00%
Operating Income	-187.35M	-260.78M	-270.71M	-264.83M	-141.06M	-55.86M
Operating Income Ratio	-81.11%	-439.64%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	-13.59M	5.99M	-17.51M	-8.25M	-1.98M	-27.66M
Income Before Tax	-200.93M	-254.80M	-288.23M	-273.08M	-143.04M	-83.51M
Income Before Tax Ratio	-86.99%	-429.55%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	5.05M	336.00K	761.00K	476.00K	213.00K	-74.00K
Net Income	-205.98M	-255.13M	-288.99M	-273.55M	-143.26M	-83.44M
Net Income Ratio	-89.18%	-430.12%	0.00%	0.00%	0.00%	0.00%
EPS	-2.22	-2.83	-3.37	-4.09	-2.41	-1.70
EPS Diluted	-2.22	-2.83	-3.37	-4.09	-2.41	-1.70
Weighted Avg Shares Out	92.97M	90.04M	85.84M	66.91M	59.52M	49.18M
Weighted Avg Shares Out (Dil)	92.97M	90.04M	85.84M	66.91M	59.52M	49.18M